NCT01387295

Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Dorte Nielsen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer. Only patients with limited extrahepatic disease are included.

Conditions

• Metastatic Breast Cancer
• Liver Metastases

Interventions

Type	Name	Description
DRUG	oxaliplatin, capecitabine, trastuzumab	Oxaliplatin intrahepatic capecitabine and trastuzumab systemic

Timeline

• Start date: 2010-04-01
• Primary completion: 2017-05-01
• Completion: 2017-09-01
• First posted: 2011-07-04
• Last updated: 2023-12-11
• Results posted: 2023-12-11

Locations

1 site across 1 country: Denmark